Related Experiment Video
Updated: Jun 18, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Complications of Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection-Many Facets of One Disease-A
Aleksandra Stasiak1, Piotr Kędziora1, Elżbieta Smolewska1
1Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50 Street, 91-738 Lodz, Poland.
Insights
Multisystem inflammatory syndrome in children (MIS-C) can cause severe cardiovascular and neurological issues following COVID-19. This case study highlights successful biological treatment for a severe MIS-C patient, emphasizing ongoing vigilance for this pediatric condition.
Area of Science:
- Pediatric infectious diseases
- Cardiovascular complications in children
- Neurological manifestations of viral infections
Background:
- Multisystem inflammatory syndrome in children (MIS-C) emerged during the COVID-19 pandemic, presenting diverse symptoms across multiple organ systems.
- MIS-C typically develops 2-6 weeks post-SARS-CoV-2 infection in pediatric patients, often leading to organ failure.
- Severe cardiovascular complications, including myocarditis and coronary artery lesions, are characteristic of MIS-C, mimicking Kawasaki disease.
Purpose of the Study:
- To present a case of severe MIS-C with significant cardiovascular and neurological involvement in a pediatric patient.
- To describe the management of severe MIS-C symptoms using biological treatment.
- To review the literature on MIS-C, highlighting its varied presentations and the need for continued physician awareness.
Main Methods:
- Case report of a pediatric patient diagnosed with severe MIS-C.
- Administration of biological treatment to manage MIS-C symptoms.
- Comprehensive literature review on MIS-C epidemiology, clinical features, and treatment.
Main Results:
- The presented case involved a severe course of MIS-C with multiple cardiovascular and neurological complications.
- Biological treatment was effective in managing the patient's severe MIS-C symptoms.
- Literature review confirmed the diverse clinical spectrum of MIS-C and the persistence of severe cases, particularly in unvaccinated children.
Conclusions:
- MIS-C remains a significant concern in pediatric populations following SARS-CoV-2 infection.
- Prompt recognition and management, including biological therapies, are crucial for severe MIS-C cases.
- Physicians must maintain vigilance for MIS-C, especially in unvaccinated children, due to its potential for severe multi-systemic complications.
Abstract:
Multisystem inflammatory syndrome in children (MIS-C) is a disease that made its mark in the early days of the COVID-19 pandemic due to the diverse course and symptoms affecting multiple body systems. It is a condition that develops in pediatric patients about 2-6 weeks after contact with a person infected with the SARS-CoV-2 virus. In many instances, MIS-C has caused multiple organ failure, with particularly severe complications involving the cardiovascular system and manifesting as hypotension, various cardiac arrhythmias, myocarditis or coronary artery lesions resembling those seen in Kawasaki disease. Currently, the incidence of MIS-C is about 1-3 per 1000 children, with a decreasing trend in recent years due to the introduction of immunization against the SARS-CoV-2 virus for children as young as 6 months. In our paper, we present the case of a patient with a severe course of MIS-C with numerous cardiovascular and neurological complications, in whom the symptoms of the disease were managed by administering biological treatment. We also present a review of the literature on the subject, which shows how many different facets this disease can have and that physicians still need to remain alert, as there are cases of severe MIS-C, especially in unvaccinated patients.
